Virus-host interaction networks as new antiviral drug targets for IAV and SARS-CoV-2

References

• Meineke R, Rimmelzwaan G, Elbahesh H. Influenza virus infections and cellular kinases. Viruses. 2019;11:2.
   Web of Science ®Google Scholar
• Chen X, Liu S, Goraya MU, et al. Host immune response to influenza A virus infection. Front Immunol. 2018;9:320.
   PubMed Web of Science ®Google Scholar
• Engelhardt OG, Fodor E. Functional association between viral and cellular transcription during influenza virus infection. Rev Med Virol. 2006;16(5):329–345.
   PubMed Web of Science ®Google Scholar
• Yewdell JW, Ince WL. Virology. Frameshifting to PA-X influenza. Science. 2012;337(6091):164–165.
   PubMed Web of Science ®Google Scholar
• Pauli EK, Schmolke M, Wolff T, et al. Influenza A virus inhibits type I IFN signaling via NF-kappaB-dependent induction of SOCS-3 expression. PLoS Pathog. 2008;4(11):e1000196.
   PubMed Web of Science ®Google Scholar
• Zhang F, Sun X, Zhu Y, et al. Downregulation of miR-146a inhibits influenza A virus replication by enhancing the type I interferon response in vitro and in vivo. Biomed Pharmacother. 2019;111:740–750.
   PubMed Web of Science ®Google Scholar
• Ouyang J, Zhu X, Chen Y, et al. NRAV, a long noncoding RNA, modulates antiviral responses through suppression of interferon-stimulated gene transcription. Cell Host Microbe. 2014;16(5):616–626.
   PubMed Web of Science ®Google Scholar
• Yu T, Ding Y, Zhang Y, et al. Circular RNA GATAD2A promotes H1N1 replication through inhibiting autophagy. Vet Microbiol. 2019;231:238–245.
   PubMed Web of Science ®Google Scholar
• Li F, Chen Y, Zhang Z, et al. Robust expression of vault RNAs induced by influenza A virus plays a critical role in suppression of PKR-mediated innate immunity. Nucleic Acids Res. 2015;43(21):10321–10337.
   PubMed Web of Science ®Google Scholar
• Liu S, Wang T, Wang M, et al. Epigenetic modification Is regulated by the interaction of influenza A virus nonstructural protein 1 with the De Novo DNA methyltransferase DNMT3B and subsequent transport to the cytoplasm for K48-linked polyubiquitination. J Virol. 2019;93:7.
   Web of Science ®Google Scholar
• Adamson CS, Chibale K, Goss RJM, et al. Antiviral drug discovery: preparing for the next pandemic. Chem Soc Rev. 2021;50(6):3647–3655.
   PubMed Web of Science ®Google Scholar
• Meganck RM, Baric RS. Developing therapeutic approaches for twenty-first-century emerging infectious viral diseases. Nat Med. 2021;27(3):401–410.
   PubMed Web of Science ®Google Scholar
• de Chassey B, Meyniel-Schicklin L, Vonderscher J, et al. Virus-host interactomics: new insights and opportunities for antiviral drug discovery. Genome Med. 2014;6(11):115.
   PubMed Web of Science ®Google Scholar
• Loregian A, Mercorelli B, Nannetti G, et al. Antiviral strategies against influenza virus: towards new therapeutic approaches. Cell Mol Life Sci. 2014;71(19):3659–3683.
   PubMed Web of Science ®Google Scholar
• Pizzorno A, Padey B, Terrier O, et al. Drug repurposing approaches for the treatment of influenza viral infection: reviving old drugs to fight against a long-lived enemy. Front Immunol. 2019;10:531.
   PubMed Web of Science ®Google Scholar
• Watanabe T, Kawaoka Y. Influenza virus-host interactomes as a basis for antiviral drug development. Curr Opin Virol. 2015;14:71–78.
   PubMed Web of Science ®Google Scholar
• Watanabe T, Kawakami E, Shoemaker J, et al. Influenza virus-host interactome screen as a platform for antiviral drug development. Cell Host Microbe. 2014;16(6):795–805.
   PubMed Web of Science ®Google Scholar
• Shaw ML. The host interactome of influenza virus presents new potential targets for antiviral drugs. Rev Med Virol. 2011;21(6):358–369.
   PubMed Web of Science ®Google Scholar
• Zhou YW, Xie Y, Tang L-S, et al. Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies. Signal Transduct Target Ther. 2021;6(1):317.
   PubMed Web of Science ®Google Scholar
• Artese A, Svicher V, Costa G, et al. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses. Drug Resist Updat. 2020;53:100721.
   PubMed Web of Science ®Google Scholar
• Liu X, Huuskonen S, Laitinen T, et al. SARS-CoV-2-host proteome interactions for antiviral drug discovery. Mol Syst Biol. 2021;17(11):e10396.
   PubMed Web of Science ®Google Scholar
• Te Velthuis AJ, Fodor E. Influenza virus RNA polymerase: insights into the mechanisms of viral RNA synthesis. Nat Rev Microbiol. 2016;14(8):479–493.
   PubMed Web of Science ®Google Scholar
• Reikine S, Nguyen JB, Modis Y, et al. Pattern recognition and signaling mechanisms of RIG-I and MDA5. Front Immunol. 2014;5:342.
   PubMed Web of Science ®Google Scholar
• Gack MU, Albrecht RA, Urano T, et al. Influenza A virus NS1 targets the ubiquitin ligase TRIM25 to evade recognition by the host viral RNA sensor RIG-I. Cell Host Microbe. 2009;5(5):439–449.
   PubMed Web of Science ®Google Scholar
• Rajsbaum R, Albrecht RA, Wang MK, et al. Species-specific inhibition of RIG-I ubiquitination and IFN induction by the influenza A virus NS1 protein. PLoS Pathog. 2012;8(11):e1003059.
   PubMed Web of Science ®Google Scholar
• Tawaratsumida K, Phan V, Hrincius ER, et al. Quantitative proteomic analysis of the influenza A virus nonstructural proteins NS1 and NS2 during natural cell infection identifies PACT as an NS1 target protein and antiviral host factor. J Virol. 2014;88(16):9038–9048.
   PubMed Web of Science ®Google Scholar
• Yan N, Chen ZJ. Intrinsic antiviral immunity. Nat Immunol. 2012;13(3):214–222.
   PubMed Web of Science ®Google Scholar
• Du Y, Yang F, Wang Q, et al. Influenza a virus antagonizes type I and type II interferon responses via SOCS1-dependent ubiquitination and degradation of JAK1. Virol J. 2020;17(1):74.
   PubMed Web of Science ®Google Scholar
• Khongnomnan K, Makkoch J, Poomipak W, et al. Human miR-3145 inhibits influenza A viruses replication by targeting and silencing viral PB1 gene. Exp Biol Med (Maywood. 2015;240(12):1630–1639.
   PubMed Web of Science ®Google Scholar
• Song L, Liu H, Gao S, et al. Cellular microRNAs inhibit replication of the H1N1 influenza A virus in infected cells. J Virol. 2010;84(17):8849–8860.
   PubMed Web of Science ®Google Scholar
• Kumar A, Kumar A, Ingle H, et al. MicroRNA hsa-miR-324-5p Suppresses H5N1 virus replication by targeting the viral PB1 and host CUEDC2. J Virol. 2018;92:19.
   Web of Science ®Google Scholar
• Ingle H, Kumar S, Raut AA, et al. The microRNA miR-485 targets host and influenza virus transcripts to regulate antiviral immunity and restrict viral replication. Sci Signal. 2015;8(406):ra126.
   PubMed Web of Science ®Google Scholar
• Wang R, Zhang Y-Y, Lu J-S, et al. The highly pathogenic H5N1 influenza A virus down-regulated several cellular MicroRNAs which target viral genome. J Cell Mol Med. 2017;21(11):3076–3086.
   PubMed Web of Science ®Google Scholar
• Cui H, Zhang C, Zhao Z, et al. Identification of cellular microRNA miR-188-3p with broad-spectrum anti-influenza A virus activity. Virol J. 2020;17(1):12.
   PubMed Web of Science ®Google Scholar
• Bavagnoli L, Campanini G, Forte M, et al. Identification of a novel antiviral micro-RNA targeting the NS1 protein of the H1N1 pandemic human influenza virus and a corresponding viral escape mutation. Antiviral Res. 2019;171:104593.
   PubMed Web of Science ®Google Scholar
• Ma YJ, Yang J, Fan X-L, et al. Cellular microRNA let-7c inhibits M1 protein expression of the H1N1 influenza A virus in infected human lung epithelial cells. J Cell Mol Med. 2012;16(10):2539–2546.
   PubMed Web of Science ®Google Scholar
• Zhao L, Zhu J, Zhou H, et al. Identification of cellular microRNA-136 as a dual regulator of RIG-I-mediated innate immunity that antagonizes H5N1 IAV replication in A549 cells. Sci Rep. 2015;5:14991.
   PubMed Web of Science ®Google Scholar
• Zhao L, Zhang X, Wu Z, et al. The downregulation of MicroRNA hsa-miR-340-5p in IAV-infected A549 cells suppresses viral replication by targeting RIG-I and OAS2. Mol Ther Nucleic Acids. 2019;14:509–519.
   PubMedGoogle Scholar
• Hsu AC, Dua K, Starkey MR, et al. MicroRNA-125a and -b inhibit A20 and MAVS to promote inflammation and impair antiviral response in COPD. JCI Insight. 2017;2(7):e90443.
   PubMed Web of Science ®Google Scholar
• Rosenberger CM, Podyminogin RL, Diercks AH, et al. miR-144 attenuates the host response to influenza virus by targeting the TRAF6-IRF7 signaling axis. PLoS Pathog. 2017;13(4):e1006305.
   PubMed Web of Science ®Google Scholar
• Wang K, Lai C, Gu H, et al. miR-194 inhibits innate antiviral immunity by targeting FGF2 in influenza H1N1 virus infection. Front Microbiol. 2017;8:2187.
   PubMed Web of Science ®Google Scholar
• Guo M, Li F, Ji J, et al. Inhibition of miR-93 promotes interferon effector signaling to suppress influenza A infection by upregulating JAK1. Int Immunopharmacol. 2020;86:106754.
   PubMed Web of Science ®Google Scholar
• Maarouf M, Chen B, Chen Y, et al. Identification of lncRNA-155 encoded by MIR155HG as a novel regulator of innate immunity against influenza A virus infection. Cell Microbiol. 2019;21(8):e13036.
   PubMed Web of Science ®Google Scholar
• Chai W, Li J, Shangguan Q, et al. Lnc-ISG20 inhibits influenza A virus replication by enhancing ISG20 expression. J Virol. 2018;92:16.
   Web of Science ®Google Scholar
• Li X, Guo G, Lu M, et al. Long noncoding RNA Lnc-MxA inhibits beta interferon transcription by forming RNA-DNA triplexes at its promoter. J Virol. 2019;93:21.
   Web of Science ®Google Scholar
• Wang Q, Zhang D, Feng W, et al. Long noncoding RNA TSPOAP1 antisense RNA 1 negatively modulates type I IFN signaling to facilitate influenza A virus replication. J Med Virol. 2022;94(2):557–566.
   PubMed Web of Science ®Google Scholar
• Zhao L, Xia M, Wang K, et al. A long Non-coding RNA IVRPIE promotes host antiviral immune responses through regulating interferon beta1 and ISG expression. Front Microbiol. 2020;11:260.
   PubMed Web of Science ®Google Scholar
• Wang J, Zhang Y, Li Q, et al. Influenza virus exploits an interferon-independent lncRNA to preserve viral RNA synthesis through stabilizing viral RNA polymerase PB1. Cell Rep. 2019;27(11):3295–3304. e4.
   PubMed Web of Science ®Google Scholar
• Wang J, Wang Y, Zhou R, et al. Host long noncoding RNA lncRNA-PAAN regulates the replication of influenza A virus. Viruses. 2018;10:6.
   Web of Science ®Google Scholar
• Wang P, Xu J, Cao X, et al. An interferon-independent lncRNA promotes viral replication by modulating cellular metabolism. Science. 2017;358(6366):1051–1055.
   PubMed Web of Science ®Google Scholar
• Qu Z, Meng F, Shi J, et al. A novel intronic Circular RNA antagonizes influenza virus by absorbing a microRNA that degrades CREBBP and accelerating IFN-beta production. mBio. 2021;12(4):e0101721.
   PubMed Web of Science ®Google Scholar
• Kohio HP, Adamson AL. Glycolytic control of vacuolar-type ATPase activity: a mechanism to regulate influenza viral infection. Virology. 2013;444(1-2):301–309.
   PubMed Web of Science ®Google Scholar
• Morita M, Kuba K, Ichikawa A, et al. The lipid mediator protectin D1 inhibits influenza virus replication and improves severe influenza. Cell. 2013;153(1):112–125.
   PubMed Web of Science ®Google Scholar
• Peretz J, Pekosz A, Lane AP, et al. Estrogenic compounds reduce influenza A virus replication in primary human nasal epithelial cells derived from female, but not male, donors. Am J Physiol Lung Cell Mol Physiol. 2016;310(5):L415–L425.
   PubMed Web of Science ®Google Scholar
• Read SA, O’Connor KS, Suppiah V, et al. Zinc is a potent and specific inhibitor of IFN-lambda3 signalling. Nat Commun. 2017;8:15245.
   PubMed Web of Science ®Google Scholar
• Luo Z, Liu L-F, Jiang Y-N, et al. Novel insights into stress-induced susceptibility to influenza: corticosterone impacts interferon-beta responses by Mfn2-mediated ubiquitin degradation of MAVS. Signal Transduct Target Ther. 2020;5(1):202.
   PubMed Web of Science ®Google Scholar
• Engel DA. The influenza virus NS1 protein as a therapeutic target. Antiviral Res. 2013;99(3):409–416.
   PubMed Web of Science ®Google Scholar
• Assil S, Webster B, Dreux M, et al. Regulation of the host antiviral state by intercellular communications. Viruses. 2015;7(8):4707–4733.
   PubMed Web of Science ®Google Scholar
• Yang C, Liu X, Cheng T, et al. LYAR suppresses beta interferon induction by targeting phosphorylated interferon regulatory factor 3. J Virol. 2019;93(21):e00769-19.
   Web of Science ®Google Scholar
• Schaefer MH, Lopes TJS, Mah N, et al. Adding protein context to the human protein-protein interaction network to reveal meaningful interactions. PLoS Comput Biol. 2013;9(1):e1002860.
   PubMed Web of Science ®Google Scholar
• Steuerman Y, Cohen M, Peshes-Yaloz N, et al. Dissection of influenza infection In vivo by single-cell RNA sequencing. Cell Syst. 2018;6(6):679–691. e4.
   PubMed Web of Science ®Google Scholar
• Ramos I, Smith G, Ruf-Zamojski F, et al. Innate immune response to influenza virus at single-cell resolution in human epithelial cells revealed paracrine induction of interferon lambda 1. J Virol. 2019;93:20.
   Web of Science ®Google Scholar
• Zhou W, Cheng X, Zhang Y, et al. Effect of Liuwei Dihuang decoction, a traditional Chinese medicinal prescription, on the neuroendocrine immunomodulation network. Pharmacol Ther. 2016;162:170–178.
   PubMed Web of Science ®Google Scholar
• Gordon DE, Jang GM, Bouhaddou M, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020;583(7816):459–468.
   PubMed Web of Science ®Google Scholar
• Hillen HS, Kokic G, Farnung L, et al. Structure of replicating SARS-CoV-2 polymerase. Nature. 2020;584(7819):154–156.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and Is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280. e8.
   PubMed Web of Science ®Google Scholar
• Bojkova D, Klann K, Koch B, et al. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets. Nature. 2020;583(7816):469–472.
   PubMed Web of Science ®Google Scholar
• Bouhaddou M, Memon D, Meyer B, et al. The global phosphorylation landscape of SARS-CoV-2 infection. Cell. 2020;182(3):685–712. e19.
   PubMed Web of Science ®Google Scholar
• Klann K, Bojkova D, Tascher G, et al. Growth factor receptor signaling inhibition prevents SARS-CoV-2 replication. Mol Cell. 2020;80(1):164–174. e4.
   PubMed Web of Science ®Google Scholar
• El Baba R, Herbein G. Management of epigenomic networks entailed in coronavirus infections and COVID-19. Clin Epigenetics. 2020;12(1):118.
   PubMed Web of Science ®Google Scholar
• Yang H, Lyu Y, Hou F, et al. SARS-CoV-2 infection and the antiviral innate immune response. J Mol Cell Biol. 2020;12(12):963–967.
   PubMed Web of Science ®Google Scholar
• Thi Nhu Thao T, Labroussaa F, Ebert N, et al. Rapid reconstruction of SARS-CoV-2 using a synthetic genomics platform. Nature. 2020;582(7813):561–565.
   PubMed Web of Science ®Google Scholar
• Kim WR, Park EG, Kang K-W, et al. Expression analyses of MicroRNAs in hamster lung tissues infected by SARS-CoV-2. Mol Cells. 2020;43(11):953–963.
   PubMed Web of Science ®Google Scholar
• Korber B, Fischer WM, Gnanakaran S, et al. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell. 2020;182(4):812–827. e19.
   PubMed Web of Science ®Google Scholar
• Bai L, Zhao Y, Dong J, et al. Coinfection with influenza A virus enhances SARS-CoV-2 infectivity. Cell Res. 2021;31(4):395–403.
   PubMed Web of Science ®Google Scholar
• Shi G, Kenney AD, Kudryashova E, et al. Opposing activities of IFITM proteins in SARS-CoV-2 infection. EMBO J. 2021;40(3):e106501.
   PubMed Web of Science ®Google Scholar
• Abbott TR, Dhamdhere G, Liu Y, et al. Development of CRISPR as an antiviral strategy to Combat SARS-CoV-2 and influenza. Cell. 2020;181(4):865–876. e12.
   PubMed Web of Science ®Google Scholar
• Ping J, Dankar SK, Forbes NE, et al. PB2 and hemagglutinin mutations are major determinants of host range and virulence in mouse-adapted influenza A virus. J Virol. 2010;84(20):10606–10618.
   PubMed Web of Science ®Google Scholar
• Challenor S, Tucker D. SARS-CoV-2-induced remission of Hodgkin lymphoma. Br J Haematol. 2021;192(3):415.
   PubMed Web of Science ®Google Scholar
• Hoshino A, Kim HS, Bojmar L, et al. Extracellular vesicle and particle biomarkers define multiple human cancers. Cell. 2020;182(4):1044–1061. e18.
   PubMed Web of Science ®Google Scholar